Kelly Fitzgerald, Assistant Clinical Professor of Genitourinary Oncology and Cancer Immunotherapy at UCSF Health, shared a post on X:
“Great talk by Arpita Desai at IKCSNA25 succinctly summarizing options in the challenging setting of IO resistance in RCC.
We are looking ahead to earlier implementation of HIF2a blockade and earlier access to trials for our patients.”
More posts featuring Kidney Cancer.